Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease

优化曲司氯铵微针输送,改善膀胱过度活动症的耐受性和患者预后

基本信息

  • 批准号:
    10546933
  • 负责人:
  • 金额:
    $ 29.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-19 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Abstract Overactive bladder (OB) is a disease that afflicts both men and women and is driven by the aging population with a prevalence estimated as high as 39% in the US and 45% for all women over 65. OB is accompanied with a significant loss of quality of life with documented increases in falls, anxiety, and depression. The muscarinic antagonists (anticholinergics) are the primary drugs for treatment, but these agents are associated with numerous side effects and drug-drug interactions leading to discontinuation of therapy in over 50% of patients in 6-12 months. Furthermore, with age there is a growing concern for anticholinergic drug overload (especially due to drug-drug interactions) leading to additional effects such as cognition impairment and other CNS affects. Studies have shown that the pharmacodynamics efficacy of muscarinic antagonists in OB therapy is strongly associated with area under the concentration-time curve (AUC) and that the many side effects are related to maximum plasma concentrations (Cmax). Oxybutynin, one of the agents with the most side effects, was formulated as an adhesive patch, which greatly reduced cholinergic side effects due to a constant effective drug concentration. Unfortunately, the patch had its own significant side effects, mainly serious skin irritations due to the permeation enhancers needed for effective delivery. Given the very large population afflicted with OB, and the many OB drugs and formulations which fail to adequately treat the disease, there remains a desperate unmet medical need for new therapy options. Multiple advantages of microneedle transdermal delivery over other transdermal methods have been documented. More recently, swellable hydrogel microneedles (HMN) have been shown to be a highly efficient and painless method for increasing the skin permeation of drugs without additives, sharps, or polymeric monomers entering the circulation. We have selected Trospium Chloride (TC), the OB drug with the best efficacy and least side effects, yet plagued by poor bioavailability and high pharmacokinetic variability for delivery via HMN. The product will be a drug-free HMN array with a TC drug reservoir to enable a tightly controlled delivery of TC, providing efficacious AUCs with consistent plasma concentrations. This self-administered patch is designed to deliver TC over the course of a week, and will be the first OB treatment with both excellent efficacy, as well as high patient compliance and satisfaction. The end result of this work will be a novel, transdermal delivery approach for TC with readily translatable PK, efficacy and initial preclinical safety data, ready to complete preclinical development activities leading to the opening of an IND. We have assembled a team of expert advisors and collaborators to ensure successful completion of this research plan.
抽象的 膀胱过度活动症 (OB) 是一种男性和女性都患有的疾病,是由人口老龄化造成的 据估计,美国的患病率高达 39%,所有 65 岁以上女性的患病率高达 45%。OB 伴随着 生活质量显着下降,跌倒、焦虑和抑郁的情况有所增加。毒蕈碱的 拮抗剂(抗胆碱能药)是主要的治疗药物,但这些药物与 众多副作用和药物间相互作用导致超过 50% 的患者停止治疗 6-12 个月内。此外,随着年龄的增长,人们越来越担心抗胆碱能药物超负荷(尤其是 由于药物之间的相互作用)导致额外的影响,例如认知障碍和其他中枢神经系统影响。 研究表明毒蕈碱拮抗剂在 OB 治疗中的药效学效果很强 与浓度-时间曲线下面积(AUC)相关,并且许多副作用与 最大血浆浓度(Cmax)。奥昔布宁是副作用最多的药物之一 配制为贴剂,由于药物持续有效,大大减少了胆碱能副作用 专注。不幸的是,该贴片有其自身的显着副作用,主要是由于以下原因引起的严重皮肤刺激: 有效递送所需的渗透促进剂。鉴于患有 OB 的人口非常多,并且 许多 OB 药物和制剂未能充分治疗该疾病,仍然有一个令人绝望的未得到满足的问题 医疗需要新的治疗选择。 与其他透皮方法相比,微针透皮给药具有多种优势 记录在案。最近,可膨胀水凝胶微针(HMN)已被证明是一种高效的 以及无痛方法,用于增加药物的皮肤渗透性,无需添加剂、锐器或聚合物 单体进入循环。我们选择了效果最好的OB药物曲司氯铵(TC) 且副作用最少,但仍受到生物利用度差和药代动力学变异性高的困扰 HMN。该产品将是一种无药物 HMN 阵列,带有 TC 药物储库,可实现严格控制的输送 TC,提供有效的 AUC 和一致的血浆浓度。这个自我管理的补丁是 旨在在一周内提供 TC,并且将是第一个具有优异疗效的 OB 治疗, 以及患者的高依从性和满意度。 这项工作的最终结果将是一种新颖的、具有易于转化的 PK 的 TC 透皮给药方法, 功效和初始临床前安全性数据,准备完成临床前开发活动,从而实现 IND 的开放。我们组建了一支由专家顾问和合作者组成的团队,以确保成功 完成本研究计划。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elke Lipka其他文献

Elke Lipka的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elke Lipka', 18)}}的其他基金

Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
用于治疗流感的新型扎那米韦自用微阵列贴片 (MAP)
  • 批准号:
    10761086
  • 财政年份:
    2023
  • 资助金额:
    $ 29.96万
  • 项目类别:
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis
用于治疗脓毒症的合成高密度脂蛋白的开发
  • 批准号:
    10384700
  • 财政年份:
    2022
  • 资助金额:
    $ 29.96万
  • 项目类别:
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis
用于治疗脓毒症的合成高密度脂蛋白的开发
  • 批准号:
    10569516
  • 财政年份:
    2022
  • 资助金额:
    $ 29.96万
  • 项目类别:
Novel, Safe, Efficacious Heparin Reversal
新颖、安全、有效的肝素逆转
  • 批准号:
    10545133
  • 财政年份:
    2022
  • 资助金额:
    $ 29.96万
  • 项目类别:
A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections
治疗生物膜肺炎感染的新型联合疗法
  • 批准号:
    9888308
  • 财政年份:
    2019
  • 资助金额:
    $ 29.96万
  • 项目类别:
New Prodrug Strategies for Cidofovir Designed for Mitigating First-Pass Metabolism
旨在减轻首过代谢的西多福韦新前药策略
  • 批准号:
    9436472
  • 财政年份:
    2018
  • 资助金额:
    $ 29.96万
  • 项目类别:
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
开发 MRS-2541,一种甲硫氨酰-tRNA 合成酶抑制剂,用于治疗革兰氏阳性细菌感染。
  • 批准号:
    10699105
  • 财政年份:
    2017
  • 资助金额:
    $ 29.96万
  • 项目类别:
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
扎那米韦微针治疗流感感染
  • 批准号:
    10614045
  • 财政年份:
    2017
  • 资助金额:
    $ 29.96万
  • 项目类别:
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
扎那米韦微针治疗流感感染
  • 批准号:
    9438857
  • 财政年份:
    2017
  • 资助金额:
    $ 29.96万
  • 项目类别:
Microneedle Delivery of Zanamivir for Treatment of Influenza
扎那米韦微针治疗流感
  • 批准号:
    10132966
  • 财政年份:
    2017
  • 资助金额:
    $ 29.96万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 29.96万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 29.96万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 29.96万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 29.96万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 29.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 29.96万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 29.96万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 29.96万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 29.96万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 29.96万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了